Sterculic Acid Treatment for Choroidal Neovascularization

Sterculic acid is a naturally occurring cyclopropene acid present in kapok seed oil, cottonseed oil, and in the seeds of the Sterculia foetida tree.  Sterculic acid has been reported to be a non-specific inhibitor of stearoyl-Co desaturase (SCD), which has been implicated in several disease states, including cardiovascular disease, obesity, non-insulin-dependent diabetes mellitus, skin disease, hypertension, neurological diseases, immune disorders and cancer (see also Ntambi JM, J. Lipid Res., 1999, 40(9):1549-1558).

Investigators at The National Eye Institute (NEI) Laboratory of Retinal Cell and Molecular Biology discovered that sterculic acid inhibits the neovascularization of the chick chorioallantonic membrane demonstrating that this compound exhibits a potent anti-angiogenic activity.  Further, the NIH investigators have shown that sterculic acid inhibits the formation of choroidal neovacularization in the retina of laser treated rats. These results suggest that sterculic acid possesses anti-angiogenic effect likely through regulating genes involved in the angiogenic process. 

The present invention is directed to methods of using sterculic acid for the treatment of inflammation, in particular, 7-ketocholesterol mediated inflammation, 7-ketocholesterol cytotoxicity, or unregulated angiogenesis.  Diseases mediated by 7-ketocholesterol-induced inflammation and 7-ketocholesterol cytotoxicity include atherosclerosis age-related macular degeneration, and Alzheimer's disease.  Diseases mediated by unregulated angiogenesis include certain cancers and age-related macular degeneration.  Also disclosed are methods of treating atherosclerosis or Alzheimer's disease using sterculic acid. Development Status: Early stage in vitro and animal model data.

Development Stage:
Pre-clinical (in vivo)


Ignacio Rodriguez ()  ➽ more inventions...

Intellectual Property:
U.S. Pat: 8.993,626 issued 2015-03-31

Collaboration Opportunity:

Licensing and research collaboration

Licensing Contact:
John Hewes, Ph.D.
Phone: 240-276-5515

OTT Reference No: E-092-2010
Updated: May 30, 2018